Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Sciences, Millipore Ink Alzheimer's Assay Deal

NEW YORK (GenomeWeb News) – Proteome Sciences and Millipore jointly announced today that they will collaborate on the development of multiplex immunoassays for Alzheimer's disease research.

Under terms of the deal, Millipore will develop the immunoassays on the Luminex platform to measure Proteome Sciences' Alzheimer's disease biomarkers. Billerica, Mass.-based Millipore will have exclusive rights to develop and sell Luminex bead-based panels for Alzheimer's research as well as other cognitive function disorders.

Cobham, UK-based Proteome Sciences retains all rights to clinical applications of the biomarkers. The firm has identified these biomarkers through a collaboration with the Institute of Psychiatry at Kings College, London.

"By expanding our portfolio of multiplex immunoassays targeting Alzheimer's disease biomarkers, we will complement our portfolio of products for neuroscience that includes antibodies and ELISAs, neural stem cells, specialty media, and cell-based high content analysis kits."

Financial terms of the alliance were not disclosed.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.